The Application Notebook
Transferring LC methods between instruments and/or laboratory sites is a common practice that allows analytical scientists to maximize equipment usage.
Kenneth J. Fountain, Hillary Hewitson and Damian Morrison, Waters Corporation, Milford, Massachusetts, USA.
Transferring LC methods between instruments and/or laboratory sites is a common practice that allows analytical scientists to maximize equipment usage. Although common, method transfer can be a difficult task. Differences in the properties of the LC system can produce gradient profiles that are inconsistent between the original method and the transferred method. The selectivity of the column must also remain constant when transferring from one LC to another. Complexity is added when methods are transferred between different technology platforms such as HPLC and UPLC. In this application, a method for clozapine and four impurities is transferred from UPLC to HPLC using the ACQUITY UPLC H-Class system. Selectivity of the separation is preserved by using columns with the same stationary phase that differ only in particle size.
UPLC system: Waters ACQUITY UPLC H-Class system with PDA detector
HPLC system: Waters Alliance 2695 separations module with 2998 PDA detector
Columns: BEH Shield RP18 1.7 to 3.5 µm method transfer kit
Mobile phase A: H2O
Mobile phase B: Acetonitrile
Mobile phase C: 200 mM ammonium formate, pH 10
Sample: USP resolution mixture for clozapine (0.144 mg/mL in 80/20 MeOH/H2O)
Detection: 257 nm
Column temp.: 30 °C
Gradient, flow rate and injection volumes are specified in the figure captions. Calculations to preserve the gradient profile were performed with the new ACQUITY UPLC columns calculator.
Figure 1: Separation of clozapine and its impurities on (a) the ACQUITY UPLC H-Class system and (b) the Alliance 2695 HPLC system. UPLC gradient is from 5 to 95% B in 5 min with a constant flow of 5% C. HPLC gradient holds at 5% B for 1.91 min and then goes to 95% B in 20.6 min with a constant flow of 5% C. UPLC flow rate is 0.5 mL/min and injection volume is 2.5 µL; HPLC flow rate is 1.17 mL/min and injection volume is 24 µL.
Figure 1(a) shows the separation of the clozapine sample on a 2.1 × 50 mm, 1.7 µm BEH Shield RP18 column at high pH. All impurities were sufficiently resolved from the main active ingredient. This method was then transferred to an HPLC system using a column with identical resolving power and selectivity [Figure 1(b)]. The system dwell volumes were measured and input into the ACQUITY UPLC columns calculator to maintain the same gradient profile. Note that the selectivity between the two separations is identical and the relative retention times of each impurity to clozapine is maintained (Table 1).
Table 1: Relative retention times of impurities to clozapine for HPLC and UPLC separations.
The combination of the ACQUITY UPLC H-Class system and column method transfer kits facilitates the transfer of LC methods between HPLC and UPLC platforms. This allows methods to be easily transferred between systems, laboratories and sites across the world without compromising separation performance.
©2010 Waters Corporation. Waters, The Science of What's Possible, ACQUITY UPLC, XBridge and Alliance are trademarks of Waters Corporation.
Waters Corporation
34 Maple Street, Milford, Massachusetts 01757, USA
tel. +1 508 478 2000 fax +1 508 478 1990
Website: www.waters.com
Testing Solutions for Metals and PFAS in Water
January 22nd 2025When it comes to water analysis, it can be challenging for labs to keep up with ever-changing testing regulations while also executing time-efficient, accurate, and risk-mitigating workflows. To ensure the safety of our water, there are a host of national and international regulators such as the US Environmental Protection Agency (EPA), World Health Organization (WHO), and the European Union (EU) that demand stringent testing methods for drinking water and wastewater. Those methods often call for fast implementation and lengthy processes, as well as high sensitivity and reliable instrumentation. This paper explains how your ICP-MS, ICP-OES, and LC-MS-MS workflows can be optimized for compliance with the latest requirements for water testing set by regulations like US EPA methods 200.8, 6010, 6020, and 537.1, along with ISO 17294-2. It will discuss the challenges faced by regulatory labs to meet requirements and present field-proven tips and tricks for simplified implementation and maximized uptime.
A Guide To Finding the Ideal Syringe and Needle
January 20th 2025Hamilton has produced a series of reference guides to assist science professionals in finding the best-suited products and configurations for their applications. The Syringe and Needle Reference Guide provides detailed information on Hamilton Company’s full portfolio of syringes and needles. Everything from cleaning and preventative maintenance to individual part numbers are available for review. It also includes selection charts to help you choose between syringe terminations like cemented needles and luer tips.
Oasis or Sand Dune? Isolation of Psychedelic Compounds
January 20th 2025Magic mushrooms, once taboo, have recently experienced a renaissance. This new awakening is partially due to new findings that indicate the effects of psilocybin, and its dephosphorylated cousin psilocin may produce long lasting results for patients who might be struggling with anxiety, depression, alcohol and drug abuse, and post-traumatic stress disorder. Hamilton Company has developed a methodology for the isolation and identification of 5 common psychedelic compounds used in the potential treatment of disease. The PRP-1 HPLC column resin remains stable in the harsh alkaline conditions ideal for better separations.
GPCRs – The Biological Traffic Modulator: Chromatographic Analysis of Peptides in the GI Tract
January 20th 2025The G protein-coupled receptors (GPCR) are found throughout the entire body and have shown significance in the development of new therapeutic treatments. Isolation of seven classic GRPC peptides initiating in the GI tract highlights the benefits of using the polymer-based PRP-3, a reversed-phase resin. The covalent bonds found in the PRP-3 exhibit advantageous interactions between the biological π bonds found in the peptides and the available aromatic benzyl rings of the resin.